Trials / Completed
CompletedNCT01337258
Economic Analyses of the REDUCE Trial
Economic Analyses Alongside the REDUCE Clinical Trial
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial. REDUCE is a 4-year, phase 3, randomized, double-blind, parallel assignment clinical trial of the use of dutasteride compared with no chemopreventive treatment. The REDUCE trial was a four-year, international, multicenter, randomized, double-blind, placebo-controlled, parallel group study. There were 790 investigators in 42 countries.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dutasteride | dutasteride 0.5mg daily. |
| DRUG | Placebo | Men taking placebo daily |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2011-04-18
- Last updated
- 2017-05-30
Source: ClinicalTrials.gov record NCT01337258. Inclusion in this directory is not an endorsement.